The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Unmet needs and therapeutic strategies in essential thrombocythemia
In this video, Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses unmet needs and therapeutic strategies being investigated in essential thrombocythemia (ET). Dr Verstovsek first highlights the high risk of thrombosis in patients with ET and the importance of exploring novel agents to reduce this risk. Dr Verstovsek then discusses the ongoing Phase III SURPASS-ET study (NCT04285086) which is comparing the use of ropeginterferon alfa-2b versus anagrelide in patients with ET. To conclude, Dr Verstovsek highlights other agents being explored in this field, including bomedemstat and pelabresib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
